Day: September 8, 2020

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

50998-17-9, (2S,4R)-l-(2-(3-Acetyl-lH-indazol-l-yl)acetyl)-4-fluoro-N-(2-fluoro-3-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)pyrrolidine-2-carboxamide (0.158 g), 6- bromoquinoxaline (0.050 g), Pd(dppf)Cl2 (39 mg) and potassium carbonate (0.165 g) were taken in a pressure tube under argon. To this mixture, 4 mL of dioxane and 1 mL of water were added. The mixture was bubbled with argon for 5 min and the vial was stoppered and subjected to microwave irradiation at 100 C for 45 min. The volatiles were removed under reduced pressure and the residue was purified by ISCO (0-2 % MeOH in CH2CI2) to afford compound 83. 1H NMR (400 MHz, DMSO) (major rotamer) delta 2.07- – 2.33 (m, 1H), 2.55-2.72 (m, 1H), 2.61 (s, 3H), 3.95-4.09 (m, 1H), 4.25 (dd, J = 12.5, 21.9 Hz, 1H), 4.79 (t, J = 8.4 Hz, 1H), 5.57 (d, J = 52.8 Hz, 1H), 5.59 (d, J = 17.2 Hz, 1H), 5.80 (d, J = 17.4 Hz, 1H), 7.28-7.49 (m, 4H), 7.69 (d, J = 8.4 Hz, 1H), 7.94 (t, J = 7.6 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H), 8.14 – 8.21 (m, 3H), 8.99 (d, J = 3.6 Hz, 2H), 10.03 (s, 1H). 19F- MR (DMSO-de ) (major rotamer): delta – 130.1, -175.9.

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; ACHILLION PHARMACEUTICALS, INC.; WILES, Jason, Allan; PHADKE, Avinash, S.; DESHPANDE, Milind; AGARWAL, Atul; CHEN, Dawei; GADHACHANDA, Venkat, Rao; HASHIMOTO, Akihiro; PAIS, Godwin; WANG, Qiuping; WANG, Xiangzhu; GREENLEE, William; (447 pag.)WO2017/35408; (2017); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

6298-37-9, Quinoxalin-6-amine is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To the reaction vessel was added example 40 (36 mg, 0.10 mmol), 6-aminoquinoxaline [6298-37-9] (15 mg, 0.10 mmol), COMU (53 mg, 0.12 mmol), DCM (1.3 mL) and DIPEA (17 m, 0.10 mmol). The reaction mixture was stirred at r.t. overnight. To the reaction mixture was added water (1.2 mL) and the mixture was filtered through a phase separator. The aqueous phase was further extracted with DCM (2 x 400 m), the organic phases were combined and concentrated in vacuo to yield the crude product which was purified by preparative HPLC (basic) to afford the title compound (0.0092g, 19%). LCMS (ES+) [M+H]+490.1892, RT 4.72 minutes (Method 20)., 6298-37-9

6298-37-9 Quinoxalin-6-amine 0, aquinoxaline compound, is more and more widely used in various.

Reference£º
Patent; UCB BIOPHARMA SRL; CHOVATIA, Prafulkumar Tulshibhai; CONNELLY, Rickki Lee; FRANKLIN, Richard Jeremy; HASLETT, Gregory William; HENRY, Alistair James; MADDEN, James; NEUSS, Judi Charlotte; NORMAN, Timothy John; PHILPS, Oliver; PITT, William Ross; RAMPALAKOS, Konstantinos; SELBY, Matthew Duncan; SELVARATNAM, Suganthan; TRANI, Giancarlo; ZHU, Zhaoning; (768 pag.)WO2019/243550; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.108229-82-9,6-Bromo-2,3-dichloroquinoxaline,as a common compound, the synthetic route is as follows.

General procedure: A mixture of substituted 7,8-dimethoxytetrazolo-[1,5-a]-quinazolin-5-amine 4 (0.001 mol) and 2,3-dichloroquiaxoline 2a-e (0.01 mol) in glacial acetic acid 10 mL containing 0.2 mL of DMF as a catalyst wa refluxed for 12-15 hr. after completion of the reaction (monitored by TLC), the reaction mixture was poured into water, the solid separated was filtered, washed with water, dried and purified by column chromatodraphy (2:8 CHCl3:EA) to furnish the desired compounds 5a-e.

108229-82-9, 108229-82-9 6-Bromo-2,3-dichloroquinoxaline 13799585, aquinoxaline compound, is more and more widely used in various.

Reference£º
Article; Srinivas; Prasanna; Ravinder; Indian Journal of Chemistry – Section B Organic and Medicinal Chemistry; vol. 53; 2; (2014); p. 238 – 242;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

1865-11-8, Methyl quinoxaline-2-carboxylate is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a stirred solution of methyl quinoxaline-2-carboxylate (1-a) (4.0 g, 21 mmol) in ethanol (50 mL) was added acetic acid (1.2 mL, 21 mmol) and Pd/C (10 wtpercent, 2.2 g, 21 mmol). The solution was degassed and then stirred under 5 kg pressure of hydrogen for 36 hours. The mixture was filtered through CELITE (diatomaceous earth) bed and the CELITE bed waswashed with excess methanol. The combined filtrate was concentrated under reduced pressure and the mixture was purified by column chromatography (25 ? 50percent ethyl acetate in petroleum ether) to provide the titled compound (1-b), which gave a proton NMR spectra consistent with theory a mass ion [ES+] of 193.2 for [M + H]., 1865-11-8

The synthetic route of 1865-11-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MERCK SHARP & DOHME CORP.; BESHORE, Douglas, C.; WU, Wen-Lian; (45 pag.)WO2017/99969; (2017); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.108229-82-9,6-Bromo-2,3-dichloroquinoxaline,as a common compound, the synthetic route is as follows.

To a solution of compound 1 (2.78 g, 0.01 mol) in DMF (50 mL), 4-aminophenol (2.18 g, 0.02 mol) was added. The reaction mixture was refluxed for 18h. After completion of the reaction, the reactionmixture was poured onto crushed ice with stirring. Then, the precipitate that formed was filtered, washed with water, dried and crystallized frompetroleum ether (80-100C) to give the title com-pound 5.Yield: 64%; (brown powder): m.p. 159-161 O C;IR (KBr, cm -1 ): 3423 (OH), 3162 (NH), 1617 (C=N).1 H NMR (DMSO-d 6 , delta , ppm): 7.04-8.11 (m, 11H,Ar-H), 9.03 (s, br, 2H, 2NH; exchangeable withD 2 O), 11.96 (s, br, 2H, 2OH; exchangeable withD 2 O). 13 C NMR (DMSO-d 6 , delta , ppm): 122.18-141.61(12Ar-C), 154.82, 154.94 (2C=N). MS (m/z), 422(M + ; 82%), 423 (M + + 1; 100%), 424 (M + + 2; 79%).Analysis: calcd. for C 20 H 15 BrN 4 O 2 (423.26): C,56.75; H, 3.57; N, 13.24%; found: C, 56.61; H, 3.74;N, 13.49%.

108229-82-9, As the paragraph descriping shows that 108229-82-9 is playing an increasingly important role.

Reference£º
Article; Abbas, Hebat-Allah S.; Al-Marhabi, Aisha R. M.; Ammar, Yousry A.; Acta poloniae pharmaceutica; vol. 74; 2; (2017); p. 445 – 458;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

74003-63-7,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.74003-63-7,3-Methylquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.

The solid (0.10 g, 0.53 mmol) was slurried in dichloromethane and oxalyl chloride (56 muL, 0.64 mmol) was added at 0 C. The mixture was warmed to room temperature and stirred for 1 hour, then concentrated to a tan solid (62 mg, 57%).

The synthetic route of 74003-63-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Pfizer Inc; US2005/43292; (2005); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

1593-08-4, 2-Formylquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a mixture of thiazolidine-2,4-dione or rhodanine(0.13 g, 1 mmol), aliphatic/aromatic aldehyde (1 mmol), and ethanol (4 ml), a portion of Fe3O4/SiO2-NH2/Cu(II) (0.15 g) was added and the mixture stirred under reflux for the required time (Table 2). The progress of the reaction was monitored by TLC (n-hexane/EtOAc, 2:1). After completion of the reaction, EtOH (3 ml) was added and the nanocatalyst was separated by an external magnet. The crude product was recrystallized from EtOH., 1593-08-4

1593-08-4 2-Formylquinoxaline 594088, aquinoxaline compound, is more and more widely used in various.

Reference£º
Article; Akhavan, Malihe; Foroughifar, Naser; Pasdar, Hoda; Khajeh-Amiri, Alireza; Bekhradnia, Ahmadreza; Transition Metal Chemistry; vol. 42; 6; (2017); p. 543 – 552;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

49679-45-0, Ethyl 3-chloroquinoxaline-2-carboxylate is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,49679-45-0

General procedure: Method A: a solution of compound 3 (1.11 g, 4.70 mmol), 3- aminophenol (622 mg, 5.70 mmol) and p-TSA, as a catalyst, in absolute ethanol (40 mL) was refluxed for 110 h. Ethanol was then evaporated under reduced pressure, and the resulting residue was purified by silica column chromatography using cyclohexane with ethyl acetate gradient (0e50%) as eluent to give the desired compound 4a (1.0 g, 69%) as a red powder.

49679-45-0 Ethyl 3-chloroquinoxaline-2-carboxylate 12283436, aquinoxaline compound, is more and more widely used in various.

Reference£º
Article; Oyallon, Bruno; Brachet-Botineau, Marie; Loge, Cedric; Bonnet, Pascal; Souab, Mohamed; Robert, Thomas; Ruchaud, Sandrine; Bach, Stephane; Berthelot, Pascal; Gouilleux, Fabrice; Viaud-Massuard, Marie-Claude; Denevault-Sabourin, Caroline; European Journal of Medicinal Chemistry; vol. 154; (2018); p. 101 – 109;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1593-08-4,2-Formylquinoxaline,as a common compound, the synthetic route is as follows.

Int-16A. (i?)-2-Methyl-N-(quinoxalin-2-ylmethylene)propane-2-sulfinamide. To a solution of commercially available quinoxaline-2-carbaldehyde (0.500 g, 3.16 mmol) in DCM (14.0 mL) were added 2-methylpropane-2-sulfinamide (0.383 g, 3.16 mmol) and Ti(OEt)4 (3.31 mL, 15.8 mmol). The reaction mixture was refluxed for 17 h at which point it was cooled to room temperature and quenched with water. After filtration of the reaction mixture through a CELITE pad and subsequent washing of the cake with DCM, the organic phase of the filtrate was separated and washed with water, sat. brine, dried over anhydrous Na2S04 and concentrated. The residue was purified by flash chromatography (silica gel, hexanes:EtOAc, 100:0 to 50:50) to yield Int-16A (0.690 g, 84%) as a tan solid. NMR (500 MHz, OMSO-de) delta 9.54 (s, 1H), 8.68 (s, 1H), 8.29 – 8.17 (m, 2H), 8.06 – 7.92 (m, 2H), 1.27 (s, 9H). HPLC retention time (Method 2): 2.132 mia; LCMS (ES): m/z 262.2 [M+H]+

1593-08-4, As the paragraph descriping shows that 1593-08-4 is playing an increasingly important role.

Reference£º
Patent; BRISTOL-MYERS SQUIBB COMPANY; ZHAO, Guohua; MIGNONE, James; (117 pag.)WO2018/89360; (2018); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9

EXAMPLE 1; 6-[3-(Piperidin-l-ylmethvDphenyllquinoxalineA mixture of 6-bromoquinoxaline (42 mg, 0.2 mmol), 3-(piperidin-l-ylmethyl)- phenylboronic acid pinacol ester hydrochloride (67 mg, 0.21 mmol), 2M aqueous sodium carbonate solution (0.3 mL, 0.6 mmol) and Pd(PPh3 )4 (7 mg, 0.006 mmol) in DME (0.6 mL) was heated to 12O0C in a sealed tube, under microwave irradiation, for 20 minutes. After cooling, the mixture was partitioned between saturated ammonium chloride solution and EtOAc (2 mL each), and the organic phase concentrated in vacuo. The residue was purified by preparative HPLC to give the title compound (34 mg, 56%) as a pale yellow- brown gum. deltaH (CDCl3) 8.88 (d, IH), 8.85 (d, IH), 8.33 (d, IH), 8.19 (d, IH), 8.08 (dd, IH), 7.75 (s, IH), 7.68 (d, IH), 7.48 (t, IH), 7.41 (d, IH), 3.69 (s, 2H), 2.46-2.63 (m, 4H), 1.59-1.72 (m, 4H), 1.40-1.53 (m, 2H). LCMS (ES+) 304 (M+H)+, RT 2.49 minutes.

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; UCB PHARMA S.A.; BUeRLI, Roland; HAUGHAN, Alan, Findlay; MACK, Stephen, Robert; PERRY, Benjamin, Garfield; RAPHY, Gilles; SAVILLE-STONES, Elizabeth, Anne; WO2010/52448; (2010); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider